Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Prognostic utility of serum YKL-40 in patients with cervical cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk factors for early death among ovarian cancer patients: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Robotic Surgery Is Less Physically Demanding Than Laparoscopic Surgery: Paired Cross Sectional Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Examining validity evidence for a simulation-based assessment tool for basic robotic surgical skills

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group
Vis graf over relationer

BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.

PRIMARY OBJECTIVE: The primary objective is to evaluate the effect of HIPEC on overall survival in patients with FIGO stage III epithelial ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease, or residual disease up to 2.5 mm in maximum dimension.

STUDY HYPOTHESIS: We hypothesize that the addition of HIPEC to primary cytoreductive surgery improves overall survival in patients with primary FIGO stage III epithelial ovarian cancer.

TRIAL DESIGN: This international, randomized, open-label, phase III trial will enroll 538 patients with newly diagnosed FIGO stage III epithelial ovarian cancer. Following complete or near-complete (residual disease ≤2.5 mm) primary cytoreduction, patients are randomly allocated (1:1) to receive HIPEC or no HIPEC. All patients will receive six courses of platinum-paclitaxel chemotherapy, and maintenance PARP-inhibitor or bevacizumab according to current guidelines.

MAJOR ELIGIBILITY CRITERIA: Patients with FIGO stage III primary epithelial ovarian, fallopian tube, or primary peritoneal cancer are eligible after complete or near-complete primary cytoreductive surgery. Patients with resectable umbilical, spleen, or local bowel lesions may be included. Enlarged extra-abdominal lymph nodes should be negative on FDG-PET or fine-needle aspiration/biopsy.

PRIMARY ENDPOINT: The primary endpoint is overall survival.

SAMPLE SIZE: To detect a HR of 0.67 in favor of HIPEC, 200 overall survival events are required. With an expected accrual period of 60 months and 12 months additional follow-up, 538 patients need to be randomized.

ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The OVHIPEC-2 trial started in January 2020 and primary analyses are anticipated in 2026.

TRIAL REGISTRATION: ClinicalTrials.gov:NCT03772028.

OriginalsprogEngelsk
TidsskriftInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Vol/bind30
Udgave nummer6
Sider (fra-til)888-892
Antal sider5
ISSN1048-891X
DOI
StatusUdgivet - jun. 2020

Bibliografisk note

© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 61425903